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Sliterature search of studies on decision making in AS.Monte Carlo simulations were
performed to estimate the number of TAVR candidates in 19 European countries and
North America.
Results: Data from 7 studies (n¼9,723 subjects) were used.The prevalence of all AS
in the elderly was 12.4%(95%CI:6.6-18.2%),and the prevalence of severe AS was
3.4% (95%CI:1.1-5.7%).Among elderly with severe AS,75.6% (95%CI:65.8-85.4%)
were symptomatic,and 40.5% (95%CI:35.8-45.1%) of these patients were not treated
surgically.Of those,40.3% (95%CI:33.8-46.7%) received TAVR.Of the high-risk
patients,5.2% were candidates.Projections showed that there are approx. 189,836
(95%CI:80,281-347,372) TAVR candidates in the European countries and 102,558
(95%CI:43,612-187,002)in North America. Annually, there are 17,712 (95%CI:7,590-
32,691) new candidates in the EU and 9,189 (95%CI:3,898-16,682) in North America.Conclusions: With a pooled prevalence of 3.4%, the burden of disease among the
elderly due to severe AS is substantial.Under current indications,approx 290,000
elderly patients with severe AS are TAVR candidates.Nearly 27,000 patients become
eligible for TAVR annually.
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Background: Since commercialization in 2007, the number of transcatheter aortic
valve replacement (TAVR) procedures has grown exponentially. Despite the
encouraging results from randomized controlled trials and registries, there is anecdotal
evidence that the utilization of TAVR varies markedly across Europe. We sought to
examine the adoption of TAVR in Western Europe.
Methods: The adoption of TAVR was investigated in 11 European countries:
Germany, France, Italy, United Kingdom, Spain, Netherlands, Switzerland, Belgium,
Portugal, Denmark, and Ireland. Data were collected from two sources: (1) lead
physicians submitted nation-speciﬁc registry data; (2) an implantation-based TAVR-
market tracker. Population data were derived from European Union sources. TAVR
penetration in each nation was determined as a measure of actual TAVR use relative to
potential use.
Results: Between 2007 and 2011, 34,317 patients underwent TAVR. Considerable
variation in TAVR utilization existed across nations. Almost half of all implants were
performed in Germany (45.9%), with Italy (14.9%) and France (12.9%) the next most
frequent implanters. Ireland accounted for the smallest proportion of implants (0.4).
There was wide variation in the number of TAVR implants per million of population.
Germany (88.7) and Portugal (6.1) accounted for the highest and lowest number of
implants per million in 2011, respectively (meanstandard deviation: 32.9  24.9).
The number of centers performing TAVR increased 9-fold from 37 in 2007 to 342 in
2011. On average, there were 0.9  0.6 TAVR centers per million of population. TheJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstrannual number of TAVR implants performed per center across nations also varied
widely (range:10 - 89). In 2011, we estimate that there were 28,400 living TAVR
recipients and 158,371 potential TAVR candidates in the 11 study nations. The
weighted average TAVR penetration rate was low: 17.9%. Germany (36.2%) and
Portugal (3.4%) had the highest and lowest TAVR penetration rates, respectively.
2012 - 2013 data will be available for presentation at TCT.
Conclusions: Despite the rapid adoption of TAVR in Europe, our ﬁndings indicate
that TAVR adoption varies markedly across Europe and remains greatly underutilized
in most nations.
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Background: Due to its speciﬁc design the selfexpanding 31mm CoreValve pros-
thesis (for annulus diameters between 26 and 29 mm) with its 4 mm landing zone can
be technically challenging. Thus the procedural results with this device might be
different from the ones with the smaller sizes. In addition the radial force of the nitinol
stent frame is larger in the 31mm device than in the smaller device sizes.
Methods: We retrospectively analyzed the procedural results of the 50 (out of over
600) patients in whom we implanted a 31mm selfexpanding CoreValve bioprosthesis
between 2011 and May 2013 and compared them to the 52 consecutive patients
implanted with a 29 mm device within the same period. Procedural results were
analyzed according to the VARC- criteria.
Results: Patients with large annuli and the 31 mm prosthesis had signiﬁcantly higher
rates of postinterventional pacemaker implantations (34% vs 19% ; p¼0.02) despite
similar implantation depths (6.9 mm vs. 6.6 mm ; p¼ns). Although not signiﬁcant,
there was a tendency towards increased rates of postinterventional aortic regurgitation
of more than mild (AR> grade 1)(14% vs.8%; p¼ns). In contrast major vascular
bleeding (2% vs. 2%), 30-day mortality (6% vs. 7.6%) and stroke/TIA (4% vs. 2 %)
were not different between the two groups.
Conclusions: Despite the technical challenges of the small (4 mm) landing zone,
procedural results with the 31mm device were similar to those with the smaller sizes of
the device. However, postinterventional pacemaker rates were signiﬁcantly higher in
the 31mm cohort despite comparable implantation depths, which might be the result of
the speciﬁc design of the device with its increased radial force.
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Background: Recent data demonstrated that transapical (TA) TAVR is associated
with post-procedural cardiac biomarker elevation in all patients (pts). The impact of
such myocardial damage after TA-TAVR remains uncertain.
Methods: Patients from the PARTNER trial (randomized and continued access
cohorts) treated with TA-TAVR who had baseline and 24h cardiac markers measured
(cardiac troponin I [cTnI] and/or creatine kinase-MB [CKMB]) were studied. Pts were
divided into tertiles (T1, T2, T3) based on the difference between the 24h and the
baseline values of each cardiac marker (DcTnI and DCKMB). Clinical and echocar-
diographic outcomes were compared between tertiles.
Results: A total of 339 pts (T1[-5.62 to 4.41 ng/mL])¼113, T2 [4.41 to 8.01 ng/
mL])¼113, T3 (8.10 to 70.13 ng/mL)¼113) were included in the DcTnI analysis,
while 415 pts (T1 [-27 to 9.3 U/L])¼138, T2 [9.4 to 21.6 U/L]¼139, T3 [22.0 to 438
U/L])¼139) were included in the DCKMB analysis. At 30 days, pts in the highest
tertile (T3) of cardiac biomarker elevation, compared with pts in the lowest tertile
(T1), had similar all-cause mortality rate (DcTnI: T3: 7.1% % vs T1: 6.2%, p¼0.7934;
DCKMB: T3: 12.3% vs T1: 6.5%, p¼0.0996) and cardiovascular mortality rate
(DcTnI: T3: 3.6% vs T1: 3.5%, p¼0.9987; DCKMB: T3: 5.9% vs T1: 4.4%,
p¼0.5629). At 1 year, although numerically higher in T3, there remained no signif-
icant difference between tertiles with respect to all-cause mortality (DcTnI: T3: 30.1%
vs T1: 22.7%, p¼0.1849; DCKMB: T3: 29.3% vs T1: 24.8%, p¼0.3704) (ﬁgure 1)
and cardiovascular mortality (DcTnI: T3: 16.8% vs T1: 14.9%, p¼0.7064; DCKMB:
T3: 17.0% vs T1: 16.6%, p¼0.9925). At 1 year, improvement of the New York Heart
Association (NYHA) functional class (DcTnI: p¼0.6599, DCKMB: p¼0.1734) andacts/POSTER/Aortic Valve Disease and Treatment B229
